Brought to you by 
Radiation Control licenses two key patents from the NIH
17 Jun 2022
Executive Summary
Radiation Control Technologies Inc. (RCT; developing a tumor cell sensitization therapy) has licensed exclusive global rights to two key patents from the National Institutes of Health. The patents cover composition and uses of RCT’s first drug candidate RCT1938 worldwide as a radiosensitizer for cancer, and to treat or prevent radiation exposure.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Radiation Control licenses two key patents from the NIH
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice